About Us Services Careers FAQ Contact Us 0
Home Healthcare IT Multiple Myeloma Therapeutics Market Size, Share and Revenue Analysis Report 2030
Multiple Myeloma Therapeutics Market

Multiple Myeloma Therapeutics Market Size, Share & Trends Analysis Report By Drug Class (Alkylating Agents, Immunomodulators, Anti-CD38 Monoclonal Antibody, Proteasome Inhibitor, Others), By Distribution Channel (Retail Pharmacies & Drug Stores, Hospital Pharmacies, Online Pharmacies) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2022-2030

Report Code: SRHI2530DR
Author : Straits Research
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Multiple Myeloma Therapeutics Market Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Alkylating Agents
        1. By Value
      3. Immunomodulators
        1. By Value
      4. Anti-CD38 Monoclonal Antibody
        1. By Value
      5. Proteasome Inhibitor
        1. By Value
      6. Others
        1. By Value
    3. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Retail Pharmacies & Drug Stores
        1. By Value
      3. Hospital Pharmacies
        1. By Value
      4. Online Pharmacies
        1. By Value
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Alkylating Agents
        1. By Value
      3. Immunomodulators
        1. By Value
      4. Anti-CD38 Monoclonal Antibody
        1. By Value
      5. Proteasome Inhibitor
        1. By Value
      6. Others
        1. By Value
    3. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Retail Pharmacies & Drug Stores
        1. By Value
      3. Hospital Pharmacies
        1. By Value
      4. Online Pharmacies
        1. By Value
    4. U.S.
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Alkylating Agents
          1. By Value
        3. Immunomodulators
          1. By Value
        4. Anti-CD38 Monoclonal Antibody
          1. By Value
        5. Proteasome Inhibitor
          1. By Value
        6. Others
          1. By Value
      2. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Retail Pharmacies & Drug Stores
          1. By Value
        3. Hospital Pharmacies
          1. By Value
        4. Online Pharmacies
          1. By Value
    5. Canada
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Alkylating Agents
        1. By Value
      3. Immunomodulators
        1. By Value
      4. Anti-CD38 Monoclonal Antibody
        1. By Value
      5. Proteasome Inhibitor
        1. By Value
      6. Others
        1. By Value
    3. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Retail Pharmacies & Drug Stores
        1. By Value
      3. Hospital Pharmacies
        1. By Value
      4. Online Pharmacies
        1. By Value
    4. U.K.
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Alkylating Agents
          1. By Value
        3. Immunomodulators
          1. By Value
        4. Anti-CD38 Monoclonal Antibody
          1. By Value
        5. Proteasome Inhibitor
          1. By Value
        6. Others
          1. By Value
      2. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Retail Pharmacies & Drug Stores
          1. By Value
        3. Hospital Pharmacies
          1. By Value
        4. Online Pharmacies
          1. By Value
    5. Germany
    6. France
    7. Spain
    8. Italy
    9. Russia
    10. Nordic
    11. Benelux
    12. Rest of Europe
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Alkylating Agents
        1. By Value
      3. Immunomodulators
        1. By Value
      4. Anti-CD38 Monoclonal Antibody
        1. By Value
      5. Proteasome Inhibitor
        1. By Value
      6. Others
        1. By Value
    3. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Retail Pharmacies & Drug Stores
        1. By Value
      3. Hospital Pharmacies
        1. By Value
      4. Online Pharmacies
        1. By Value
    4. China
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Alkylating Agents
          1. By Value
        3. Immunomodulators
          1. By Value
        4. Anti-CD38 Monoclonal Antibody
          1. By Value
        5. Proteasome Inhibitor
          1. By Value
        6. Others
          1. By Value
      2. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Retail Pharmacies & Drug Stores
          1. By Value
        3. Hospital Pharmacies
          1. By Value
        4. Online Pharmacies
          1. By Value
    5. Korea
    6. Japan
    7. India
    8. Australia
    9. Taiwan
    10. South East Asia
    11. Rest of Asia-Pacific
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Alkylating Agents
        1. By Value
      3. Immunomodulators
        1. By Value
      4. Anti-CD38 Monoclonal Antibody
        1. By Value
      5. Proteasome Inhibitor
        1. By Value
      6. Others
        1. By Value
    3. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Retail Pharmacies & Drug Stores
        1. By Value
      3. Hospital Pharmacies
        1. By Value
      4. Online Pharmacies
        1. By Value
    4. UAE
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Alkylating Agents
          1. By Value
        3. Immunomodulators
          1. By Value
        4. Anti-CD38 Monoclonal Antibody
          1. By Value
        5. Proteasome Inhibitor
          1. By Value
        6. Others
          1. By Value
      2. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Retail Pharmacies & Drug Stores
          1. By Value
        3. Hospital Pharmacies
          1. By Value
        4. Online Pharmacies
          1. By Value
    5. Turkey
    6. Saudi Arabia
    7. South Africa
    8. Egypt
    9. Nigeria
    10. Rest of MEA
    1. Introduction
    2. By Drug Class
      1. Introduction
        1. Drug Class By Value
      2. Alkylating Agents
        1. By Value
      3. Immunomodulators
        1. By Value
      4. Anti-CD38 Monoclonal Antibody
        1. By Value
      5. Proteasome Inhibitor
        1. By Value
      6. Others
        1. By Value
    3. By Distribution Channel
      1. Introduction
        1. Distribution Channel By Value
      2. Retail Pharmacies & Drug Stores
        1. By Value
      3. Hospital Pharmacies
        1. By Value
      4. Online Pharmacies
        1. By Value
    4. Brazil
      1. By Drug Class
        1. Introduction
          1. Drug Class By Value
        2. Alkylating Agents
          1. By Value
        3. Immunomodulators
          1. By Value
        4. Anti-CD38 Monoclonal Antibody
          1. By Value
        5. Proteasome Inhibitor
          1. By Value
        6. Others
          1. By Value
      2. By Distribution Channel
        1. Introduction
          1. Distribution Channel By Value
        2. Retail Pharmacies & Drug Stores
          1. By Value
        3. Hospital Pharmacies
          1. By Value
        4. Online Pharmacies
          1. By Value
    5. Mexico
    6. Argentina
    7. Chile
    8. Colombia
    9. Rest of LATAM
    1. Multiple Myeloma Therapeutics Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Rhizen Pharmaceuticals S.A.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Johnson and Johnson
    3. Terpenoid Therapeutics Inc.
    4. Ablynx NV
    5. Acceleron Pharma Inc.
    6. IGF Oncology LLC.
    7. ImmunGene Inc.
    8. Millennium Pharmaceuticals Inc.
    9. AB Science SA
    10. AbbVie Inc.
    11. Mirna Therapeutics
    12. RedHill Biopharma Ltd.
    13. Teva Pharmaceutical Industries Ltd.
    14. TG Therapeutics Inc.
    15. MimiVax LLC
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Melanoma Therapeutics Market Size The global melanoma therapeutics market size was valued at USD 8.65 billion in 2023. It is projected to reach USD 19.87 billion by 2032, growing at a CAGR of 10.80% during the forecast period (2024–2032). Mela
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.